Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences
- 1 July 1997
- journal article
- Published by Springer Nature in Drug Information Journal
- Vol. 31 (3), 771-788
- https://doi.org/10.1177/009286159703100319
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- THE PRESCRIPTION DRUG USER FEE ACT OF 1992 AND THE NEW DRUG DEVELOPMENT PROCESSClinical Journal of Sport Medicine, 1997
- THE NEW DRUG APPROVALS OF 1993, 1994, AND 1995Clinical Journal of Sport Medicine, 1997
- A NEW LOOK AT UNITED STATES DRUG DEVELOPMENT AND APPROVAL TIMESClinical Journal of Sport Medicine, 1996
- The Prescription Drug User Fee Act of 1992PharmacoEconomics, 1996
- R&D Costs, Innovative Output and Firm Size in the Pharmaceutical IndustryInternational Journal of the Economics of Business, 1995
- Research and Development Costs for New Drugs by Therapeutic CategoryPharmacoEconomics, 1995
- New drug development in the United States from 1963 to 1992Clinical Pharmacology & Therapeutics, 1994
- Are Initiatives to Speed the New Drug Approval Process Working?Drug Information Journal, 1992
- Therapeutic Ratings and End‐of‐Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs Kenneth I. Kaitin, PhDThe Journal of Clinical Pharmacology, 1991